<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Feb. 20, 2018 (HealthDay News) — For adults with inadequately controlled type 2 diabetes, ertugliflozin treatment is associated with improved glycemic control over 52 weeks, according to a study published online Feb. 8 in Diabetes, Obesity and Metabolism<\/i>.<\/p>\n
Ronnie Aronson, M.D., from LMC Diabetes & Endocrinology in Ontario, and colleagues conducted a phase III randomized trial to examine the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 diabetes despite diet and exercise. The study comprised a 26-week placebo-controlled period where 461 participants received placebo or ertugliflozin (5 or 15 mg\/day) and a second 26-week period in which participants in the placebo group had blinded metformin added.<\/p>\n
The researchers found that the mean change in glycated hemoglobin (HbA1c) from baseline to week 52 was \u22120.9 and \u22121 percent in the ertugliflozin 5- and 15-mg groups, respectively; the proportion of patients with HbA1c <7 percent was 25.6 and 28.5 percent, respectively, at week 52. Ertugliflozin was correlated with a reduction in fasting plasma glucose, body weight, and systolic blood pressure. In females, the incidence of genital mycotic infections (GMIs) was significantly higher in both the 5- and 15-mg ertugliflozin groups versus placebo\/metformin (26.9 and 29 versus 9.9 percent); males had significantly higher GMI incidence in the 15-mg group (7.8 versus 1.2 percent).<\/p>\n
“Ertugliflozin treatment over 52 weeks improved glycemic control and reduced body weight and systolic blood pressure but increased GMIs,” the authors write.<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including Pfizer and Merck & Co., which funded the study.<\/p>\n
Abstract<\/a><\/p>\n Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n